SUBSTITUTED 6-BENZYL-4-OXOPYRIMIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Abstract: The invention concerns novel substituted 6-benzyl-4-oxopyrimidines of general formula (A). These compounds inhibit reverse transcriptase encoded by human immunodeficiency virus (HIV) or pharmaceutically acceptable salts thereof, and find their application in the prevention and treatment of HIV infection and the treatment of the resulting acquired immune deficiency syndrome (AIDS). Pharmaceutical compositions containing the compounds and a method of use of the present compounds and other agents for the treatment of AIDS and viral infection by HIV are also envisaged.

Description: SUBSTITUTED 6-BENZYL-4-OXOPYRIMIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM The present invention is concerned with compounds which inhibit the reverse transcriptase encoded by human immunodeficiency virus (HIV) or pharmaceutically acceptable salts thereof and are of value in the prevention of infection by HIV, the treatment of infection by HIV and the treatment of the resulting acquired immune deficiency syndrome (AIDS). It also relates to pharmaceutical compositions containing the compounds and to a method of use of the present compounds and other agents for the treatment of AIDS arid viral infection by HIV. BACKGROUND OF THE INVENTION A retrovirus designated human immunodeficiency virus (HIV) is the etiological agent of the complex disease that includes progressive destruction of the immune system (acquired immune deficiency syndrome; AIDS) and degeneration of the central and peripheral nervous system. Currently available drugs for AIDS therapy are divided into two groups: those that prevent infection of target cells [nucleoside (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs)], and those that prevent HIV- 1 -infected cells from yielding infectious viruses (protease inhibitors). Monotherapy with antiretroviral agents has shown limited effects, very likely due to the interplay of phenomena such as: high viral loads and multiplication rates of HIV, incomplete inhibition of viral replication and emergence of drug resistant mutants. For this reason, combination therapies with two or more drugs have been proposed for a more effective treatment of AIDS. Potent suppression of HIV replication over prolonged periods has been accomplished with regimens including reverse transcriptase and protease inhibitors, although on stopping therapies viraemia has rapidly reappeared. In the attempt to obtain better results, research is now focused on exploiting new targets and enhancing the activity of "old" drugs. Among the latter, NNRTs possibly endowed with better pharmacokinetic profiles, capability to inhibit clinically relevant mutants and, hopefully, to minimize HIV multiplication are being pursued. Compounds of the present invention are dihydro-alkyloxy-benzyl-oxopyrimidines (DABOs) which potently inhibit HIV multiplication targeting reverse transcriptase without bioactivation. BRIEF DESCRIPTION OF THE INVENTION Novel compounds of formula A: as herein defined, are disclosed. These compounds are useful in the inhibition of HIV reverse transcriptase, the prevention of infection by HIV, the treatment of infection by HIV and in the treatment of AIDS, either as compounds, pharmaceutically acceptable salts (when appropriate), pharmaceutical composition ingredients, whether or not in combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines. Methods of treating AIDS, methods of preventing infection by HIV, and methods of treating infection by HIV are also disclosed. DETAILED DESCRIPTION OF THE INVENTION AND PREFERRED EMBODIMENTS This invention is concerned with the compounds of formula A described below, combinations thereof, or pharmaceutically acceptable salts thereof, in the inhibition of HIV reverse transcriptase, the prevention or treatment of infection by HIV and in the treatment of the resulting acquired immune deficiency syndrome (AIDS). The compounds of this invention include those with structural formula A: wherein: X is -O, -CH,, -CHK (wherein K is -H, -C,. 4 alkyl, -C^Cycloalkyl), -S, -NK (wherein K is -H, -Cl, .4 alkyl, -C 3 . ft cycloalkyl), -aryl, -arylalkyl; R is -H, -C, .4 alkyl (containing one or more of heteroatoms like 0, S, N), -C 3 . 6 cycloalkyl (containing one or more of heteroatoms like 0, S, N), -aryl, -arylakl, heterocycle; Y is -H, -C, 4 alkyl, -C 3.ft cycloalkyl; Z is -H, -C,. 4 alkyl, -C 3 . ft cycloalkyl; R, is -H, -C, . alkyl, -halogen, -NO,, -OW (wherein W is -H, -CH 3 , aryl), -SW (wherein W is -H, -CH 3 , -aryl); R, is -H, -C, .4 alkyl, -halogen, -NO,, (wherein W is -H, -CH 3 , -aryl); -SW (wherein W is -H, -CH 3 , -aryl); R 3 is -H, -C, .4 alkyl, -halogen, -NO,, -OW (wherein W is -H, -CH 3 , -aryl); -SW (wherein W is -H, -CH 3 , -aryl) R 4 is -H, -C^alkyl, -halogen, -NO,, -OW (wherein W is -H, -CH 3 , -aryl); -SW (wherein W is -H, -CH 3 ,-aryl) R 5 is -H, -C 1.4 alkyl, -halogen, -NO,, -OW (wherein W is -H, -CH 3 , -aryl), -SW (wherein W is -H, -CH3, -aryl); pharmaceutically acceptable salts or soluble derivatives thereof; preparation process of derivatives thereof; a method of preventing infection of HIV, or of treating infection by HIV or of treating AIDS, comprising administering to a mammal an effective amount of compounds claimed; a pharmaceutical composition useful for inhibiting HIV reverse transcriptase, comprising an effective amount of compounds claimed, and a pharmaceutically acceptable carrier; a pharmaceutical composition useful for preventing or treating infection of HIV or for treating AIDS, comprising an effective amount of compounds claimed, and a pharmaceutically acceptable carrier. The most preferred compounds of this invention are those of table 1. The compounds of the present invention may have asymmetric centers and occur as racemates, racemic mixtures, individual diastereomers, or enantiomers. with all isomeric forms being included in the present invention. When any variable occurs more than one time in any constituent or in formula A of this invention, its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. As used herein except where noted, "alkyl" is intended to include both branched- and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms; "Halogen" or "Hal" as used herein, means fluoro, chloro, bromo and iodo. As used herein, with exceptions as noted, "aryl" is intended to mean any stable monocyclic. bicyclic or tricyclic carbon ring of up to 7 members in each ring, wherein at least one ring is aromatic. Examples of such aryl elements include phenyl, naphthyl, tetrahydronaphthyl, biphenyl. The term heterocycle or heterocyclic, as used herein except where noted represents a stable 5- to 7-membered monocyclic or stable 8- to 11 -membered bicyclic heterocyclic ring which is either saturated or unsaturated, and which consists of carbon atoms and from one to three heteroatoms selected from the group consisting of N, 0 and S; and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized, and including any bicyclic group in which any of the above- defined heterocyclic rings is fused to a benzene ring. The heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure. The pharmaceutically-acceptable salts of the novel compounds of this invention that are capable of salt formation (in the form of water- or oil- soluble or dispersible products) include the conventional non-toxic salts or the quaternary ammonium salts of these compounds, which are formed, e.g.; from inorganic or organic acids or bases. In preferred embodiments, a compound of the present invention is administered in combination or alternation with AZT, D4T, FTC (2'.3'-dideoxy-3'-thia-5-fluorocytidine); 3TC (Epivir, Glaxo Wellcome, Inc.), AZDU (3'-Azido-2\3'-dideoxyuridine); 141W94 (amprenavir. Glaxo Wellcome, Inc.); Viramune (nevirapine). Rescriptor (delavirdine); or DMP-266 (efavirenz). Other examples of antiviral agents that can be used in combination or alternation with the compounds disclosed herein for HIV therapy include DDI, DDC, Delaviridine, β-LddA, β-L-3'-azido-d5FC, carbovir, acyclovir, interferon, stavudine, CS-92 (3'-azido-2',3'-dideoxy-5-methyl-cytidine), 3'-azido nucleosides, and β-D-dioxolane nucleosides such as β-D-dioxolanylguanine (DXG), β-D-dioxolanyl-2,6-diaminopurine (DAPD), and β-D-dioxolanyl-6-chloropurine (ACP). Preferred protease inhibitors include indinavir ({l(l,S,2R),5(S)]-2,3,5-trideoxy-N- (2,3-dihydro-2-hydroxy-lH-inden-l-yl)-5-[2-[[(l,l-dimethylethyl)amino]carbonyl]-4-(3- pyridinylmethyl)-l-piperazinyl]-2-(phenylmethyl)-D-erythro-pentoamide sulfate; Merck), nelfinavir (Agouron), ritonavir (Abbot), and saquinavir (Invirase; Roche). Nonlimiting examples of other compounds that can be administered in combination or alternation with the compounds of the present invention to augment the properties of the drug on administration include abacavir: (lS,4R)-4-[2-amino-6-cyclopropyl-amino)-9H-purin-9- yl]-2-cyclopentene-l-methanol succinate (1592U89, a carbovir analog; Glaxo Wellcome); zidovudine: AZT, 3'-azido-3'-deoxythymidine (Glaxo Wellcome); BILA 1906: N-{lS-[[[3- [2S-{(l,l-dimethylethyl)amino]carbonyl}-4R-]3-pyridinylmethyl)thio]-l-piperidinyl]-2R- hydroxy-lS-(phenylmethyl)propyl]amino]carbonyl]-2-methylpropyl}-2- quinolinecarboxamide (Bio Mega/Boehringer-Ingelheim); BILA 2185: N-(l,l- dimethylethyl)-l-[2S-[[2-2,6-dimethylphenoxy)-l-oxoethyl]amino]-2R-hydroxy-4- phenylbutyl]4R-pyridinylthio)-2-piperidinecarboxamide (Bio Mega/Boehringer-Ingelheim); BM+51.0836:triazoloisoindolinone derivative; BMS 186,318: aminodiol derivative HIV-1 protease inhibitor (Bristol-Myers-Squibb); d4API: 9-[2,5-dihydro-5-(phosphonomethoxy)-2- furaneljadenine (Gilead); stavudine: d4T, 2',3'-didehydro-3'-deoxythymidine (Bristol-Myers- Squibb); efavirenz: DMP-266, a l,4-dihydro-2H-3, l-benzoxazin-2-one; HBY097: S-4- isopropoxycarbonyl-6-methoxy-3-(methylthio-methyl)-3,4-dihydroquinoxalin-2(lH)-thione; HEPT: l-[(2-hydroxyethoxy)methyl]6-(phenylthio)thymine; KNI-272: (2S,3S)-3-amino-2- hydroxy-4-phenylbutyric acid-containing tripeptide; L-697,593; 5-ethyl-6-methyl-3-(2- phthalimido-ethyl)pyridin-2(lH)-one; L-735,524: hydroxy-aminopentane amide HIV-1 protease inhibitor (Merck); L-697,661: 3-{[(-4,7-dichloro-l,3-benzoxazol-2- yl)methyl]amino}-5-ethyl-6-methylpyridin-2(lH)-one; L-FDDC: (-)-β-L-5-fluoro-2',3'- dideoxycytidine; L-FDOC: (-)-β-L-5-fluoro-dioxolane cytosine; 6-benzyl-l-ethoxymethyl-5- isopropyluracil (I-EBU; Triangle/Mitsubishi); nevirapine: l l-cyclopropyl-5,ll-dihydro-4- methyl-6H-dipyridol[3,2-b:2',3'-e]diazepin-6-one (Boehringer-Ingelheim); PFA: phosphonoformate (foscarnet; Astra); PMEA: 9-(2-phosphonylmethoxyethyl) adenine (Gilead); PMPA: (R)-9-(2-phosphonyl-methoxypropyl)adenine (Gilead); Ro 31-8959: hydroxythethylamine derivative HIV-1 protease inhibitor (Roche); RPI-3121: peptidyl protease inhibitor, l-[(3s)-3-(n-alpha-benzyloxycarbonyl)-l-asparginyl)-amino-2-hydroxy-4- phenylbutyryl]-n-tert-butyl-l-proline amide; 2720: 6-chloro-3,3-dimethyl-4- (isopropenyloxycarbonyl)-3,4-dihydro-quinoxalin-2(lH)thione; SC-52151: hydroxyethylurea isostere protease inhibitor (Searle); SC-55389A: hydroxyethyl-urea isostere protease inhibitor (Searle); TIBO R82150: (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2- butenyl)imidazo[4,5,l-jk][l,4]-benzodiazepin-2(lH)-thione (Janssen); TIBO 82913: (+)-(5S)- 4,5,6,7,-tetrahydro-9-chloro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5,ljk]- [1.4]benzodiazepin-2(lH)-thione (Janssen); TSAO-m3T:[2',5'-bis-O-(tert- butyldimethylsilyl)-3'-spiro-5'-(4'-amino- ,2'-oxathiole-2',2'-dioxide)]- β-D- pentofuranosyl-N3-methylthymine; U90152: l-[3-[(l-methylethyl)-amino]2-pyridinyl]-4-[[5- [(methylsulphonyl)-amino]-lH-indol-2yl]carbonyl]piperazine; UC: thiocarboxanilide derivatives (Uniroyal); UC-781 =N-[4-chloro-3-(3-methyl-2-butenyloxy)phenyl]-2-methyl-3- furancarbothioamide; UC-82 = N-[4-chloro-3-(3-methyl-2-butenyloxy)phenyl]-2-methyl-3- thiophenecarbothioamide; VB 11,328: hydroxyethylsulphonamide protease inhibitor (Vertex); VX-478: amprenavir, 141 W94, hydroxyethylsulphonamide protease inhibitor (Vertex/Glaxo Wellcome); XM 323: cyclic urea protease inhibitor (Dupont Merck), delaviridine (Pharmacia Upjohn), famciclovir, gancyclovir, and penciclovir. In another embodiment^ compound of the present invention is administered in combination with LG1350, which has the following structure. Preparation Of Methyl Arylacetylalkylacetates SCHEME A Meldrum's acid Anhydrous pyridine (400 mmoles, 32.5 ml) was added with stirring under nitrogen atmosphere into an ice-cooled solution of 2,2-dimethyl-l,3-dioxane-4,6-dione (Meldrurm's acid) (165 mmoles, 23.75 g) in anhydrous dichloromethane (50 ml). The resulting solution was treated, over a 2 h period at 0°C under nitrogen atmosphere, with a solution of crude arylacetyl chloride in anhydrous dichloromethane (50 ml). Arylacetyl chloride was prepared before use by refluxing the proper arylacetic acid (43.2 mmoles) with thionyl chloride (21.3 ml) under nitrogen atmosphere for 2 h. Then, the mixture was stirred for 2 h at room temperature, poured into crushed ice and treated with 2N HC1 (100 ml). The organic layer was separated and the aqueous solution was extracted twice with dichloromethane (25 ml). The organic phase and the extracts were combined, washed with brine, dried and evaporated. The solid residue was dissolved in anhydrous methanol (250 ml) and the solution was refluxed for 20 h. After cooling, metal sodium (0.16 g-atoms, 3.68 g) was carefully added and the mixture was stirred until dissolution was complete. Alkyl halide (160 mmoles) was dropped into the solution and the resulting mixture was heated at reflux for 4-12 h. After cooling, the solvent was removed and the residue treated with water (200 ml) and extracted with chloroform (3 x 100 ml). The organic layer was washed with brine (2 x 100 ml), dried and evaporated to give the desired compound, which was purified by passing through a silica gel column (chloroform as eluent). In the above reaction, arylacetic acid (Scheme "A") or arylacetyl chloride can be replaced with the corresponding 1-arylacetylimidazolide (Scheme "B") or with arylacetylethoxycarbonylanhydride. whereas the Meldrum's acid can be replaced with ethyl acetylacetate, ethyl alkylmalonate or ethyl alkylmalonate potassium salt, to give the proper ethyl arylacetylalkylacetates in high yields. Preparation Of Compounds (I) With X = O (Scheme A). The proper methyl arylacetylalkylacetate (10 mmoles) in methanol (50 ml) was added to a well-stirred suspension of O-methylisourea hydrogen sulphate (15 mmoles, 2.58 g) and calcium hydroxide (16 mmoles, 1.18 g) in water (50 ml). The resulting mixture was stirred at room temperature for 72 h, then concentrated, made acid (pH 5) with 0.5N acetic acid and extracted with ethyl acetate (3 x 50 ml). The combined organic extracts were washed with brine (100 ml), dried and evaporated to dryness. The residue was purified by crystallization from the proper solvent yielding pure 5-alkyl-6-benzyl-3,4-dihydro-2-methoxypyrimidin-4- one. This compound was then refluxed with the proper potassium alkoxide (100 mmoles of potassium metal in 20-30 ml of alcohol freshly distilled on sodium metal) under nitrogen atmosphere until starting material disappeared at the TLC control. After cooling, the mixture was concentrated, made acid (pH 5) with 0.5N acetic acid and extracted with ethyl acetate (3 x 50 ml). The combined extracts were washed once with brine (100 ml), dried and evaporated to give the required 2-alkoxy-5-alkyl-6-benzyl-3,4-dihydropyrimidin-4-one derivative, which was recrystallized from a suitable solvent or purified by column chromatography (silica gel; ethyl acetate: chloroform 1:1). Physical and chemical data of representative compounds of the invention are reported in table 1; cytotoxicity and anti-HIV- 1 activity data are reported in table 2. Preparation Of Compounds (I) With X = S SCHEME B The proper ethyl arylacetylalkylacetate (31.5 mmoles) was successively added to a stirred solution of sodium metal (0.063 g-atoms) in 50 mL of absolute ethanol (50 ml) thiourea (43 mmoles). The mixture was heated while stirring at reflux for 5 h. After cooling, the solvent was distilled in vacuo at 40-50°C until dryness and the residue was dissolved in water (200 mL) and made acid (pH 5) with 0.5N acetic acid. The resulting precipitate (the crude 2-thiouracil derivative) was filtered under reduced pressure, washed with diethyl ether, vacuum dried at 80°C for 12 h and then crystallized from the proper solvent. Then, according to method A, iodomethane (8 mmoles, 1.13 g) was added to a suspension containing the proper 2-thiouracil derivative (4 mmoles) in anhydrous N,N- dimethylformamide (2 ml), and the resulting mixture was stirred at room temperature until the starting material disappeared at the TLC control (silica gel; n-hexane: ethyl acetate: methanol 12:3:1). Then the reaction content was poured on cold water (100 mL) and extracted with ethyl acetate (3 x 50 ml). The organic layers were collected, washed with a sodium thiosulfate solution (100 ml), brine (3 x 50 ml), dried and evaporated to furnish the crude 5-alkyl-6-benzyl-3,4-dihydro-2-methylthiopyrimidin-4-one (2) as a solid purified by crystallization. Alternatively, according to methods B and C, potassium carbonate (4.2 mmoles) and the proper alkyl halide (4.4 mmoles) were added to a suspension containing 2-thiouracil derivative (4 mmoles) in anhydrous N,N-dimethylformamide (2 ml). The resulting mixture was stirred at room temperature (method B) or at 80°C (method C) until starting material disappeared at the TLC control (silica gel; n-hexane:ethyl acetate:methanol 12:3:1). Then the reaction content was poured on cold water (200 mL), made acid (pH 5) with 0.5N acetic acid and extracted with ethyl acetate (3 x 50 ml). The organic layers were collected, washed with a sodium thiosulfate solution (100 ml), brine (100 ml), dried and evaporated to furnish 5- alkyl-6-benzyl-3,4-dihydro-2-methylthiopyrimidin-4-ones (3) and (4) as crude material which was then purified by column chromatography on silica gel (eluent: n-hexane:ethyl acetate:methanol 12:3:1) followed by crystallization. Physical and chemical data of representative compounds of the invention are reported in table 1. Cytotoxicity and anti- HIV-1 activity in vitro are reported in table 2. Preparation Of Compounds (I) With X = NK SCHEME C rea Title derivatives were prepared according to the procedure described for the synthesis of compounds with X = S (I), using ethyl arylacetylalkylacetates and guanidine [2-amino-6- benzylpyrimidin-4-ones (5)] as starting materials. 2-Alkylaminoderivatives (6) were synthesized by heating the previously reported 5-alkyl-6-benzyl-3.4-dihydro-2-methylthio pyrimidin-4-ones with 20-30 ml of proper amine in a sealed tube at 170°C for 24 h. Physical and chemical data of some compounds (6) are reported in table 1. Cytotoxicity and anti-HIV- 1 activity in vitro are reported in table 2. The compounds of the present invention are useful in the inhibition of HIV reverse transcriptase, the prevention or treatment of infection by the human immunodeficiency virus (HIV) and the treatment of consequent pathological conditions such as AIDS. Treating AIDS or preventing or treating infection by HIV is defined as including, but not limited to, treating a wide range of states of HIV infection: AIDS, ARC (AIDS related complex), both symptomatic and asymptomatic, and actual or potential exposure to HIV. For example, the compounds of this invention are useful in treating infection by HIV after suspected past exposure to HIV by, e.g., blood transfusion, organ transplant, exchange of body fluids, bites, accidental needle stick, or exposure to patient blood during surgery. The compounds of this invention are also useful in the preparation and execution of screening for antiviral compounds. For example, the compounds of this invention are useful for isolating enzyme mutants, which are excellent screening tools for more powerful antiviral compounds. Furthermore, the compounds of this invention are useful in establishing or determining the binding site of other antiviral to HIV reverse transcriptase e.g., by competitive inhibition. Thus the compounds of this invention are commercial products to be sold for these purposes. For inhibition of HIV reverse transcriptase, the prevention or treatment of infection by HIV and the treatment of AIDS or ARC, the compounds of the present invention may be administered orally, parenterally (including subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques), by inhalation spray, or rectally, in dosage unit formulations containing conventional non toxic pharmaceutically-acceptable carriers, adjuvants and vehicles. Thus, in accordance with the present invention there is further provided a method of treating and a pharmaceutical composition for treating HIV infection and AIDS. The treatment involves administering to a patient in need of such treatment a pharmaceutical composition comprising a pharmaceutical carrier and a therapeutically effective amount of a compound of the present invention. These pharmaceutical compositions may be in the form of orally administrable suspensions or tablets; nasal sprays: sterile injectable preparations, for example, as sterile injectable aqueous or oleagenous suspensions or suppositories. When administered orally as a suspension, these compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may contain microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweetners/flavoring agents known in the art. As immediate release tablets, these compositions max. contain microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants known in the art. When administered by nasal aerosol or inhalation, these compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art. The injectable solutions or suspensions may be formulated according to known art, using suitable non toxic, parenterally acceptable diluents or solvents, such as mannitol, 1,3- butanediol, water. Ringer's solution or isotonic sodium '.'hloride solution, or suitable dispersing or wetting and suspending agents, such as sterile, bland, fixed oils, including synthetic mono- or diglycerides, and fatty acids, including oleic acid. When rectally administered in the form of suppositories, these compositions may be prepared by mixing the drug with a suitable non-irritating excipient; such as cocoa buffer, synthetic glyceride, esters or polyethylene glycols, which are solid at ordinary temperatures, but liquidity and/or dissolve in the rectal cavity to release the drug. The compounds of this invention can be administered orally to humans in a dosage range of 1 to 75 mg/kg body weight. One preferred dosage range is 1 to 50 mg/kg body weight orally. Another preferred dosage range is 5 to 75 mg/kg body weight orally. It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy. The present invention is also directed to combinations of the HIV reverse transcriptase inhibitor compounds with one or more agents useful in the treatment of AIDS. The compounds of this invention can be administered in combination with other compounds that are HIV reverse transcriptase inhibitors, and/or with compounds that are HIV protease inhibitors. When used in a combination treatment vith compounds of the instant invention, dosage levels of HIV protease inhibitors of the order of 1 to 25 or 50 grams-per-day are useful in the treatment or prevention of the above-indicated conditions, with oral doses two- to-five time higher. For example, infection by HIV is effectively treated by the administration of from 5 to 25 milligrams of the HIV protease inhibitor per kilogram of body weight from one to three times per day. It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy. Dosages of HIV reverse transcriptase inhibitors, when used in a combination treatment with compounds of the present invention, are comparable to those dosages specified above for the present compounds. It will be understood that the scope of combinations of the compounds of this invention with AIDS antivirals includes any combination with any pharmaceutical composition useful for the treatment of AIDS. ANTIVIRAL ASSAY PROCEDURES Compounds. Compounds were solubilized in DMSO at 200 mM and then diluted into culture medium. Cells and viruses. MT-4, C8166, H9/IIIB and CEM cells were grown at 37 °C in a 5% CO, atmosphere in RPMI 1640 medium, supplemented with 10% fetal calf serum (FCS), 100 IU/mL penicillin and 100 μg/mL streptomycin. Cell cultures were checked periodically for the absence of mycoplasma contamination with a MycoTect Kit (Gibco). Human immunodeficiency virus type-1 (HIV-1, III B strain) was obtained from supematants of persistently infected H9/III B cells. HIV-1 stock solution had a titres of 4.5xl0 6 50% cell culture infectious dose (CCID 50 )/ml. HIV titration. Titration of HIV was performed in C8166 cells by the standard limiting dilution method (dilution 1:2, four replica wells per dilution) in 96-well plates. The infectious virus titre was determined by light microscope scoring of cvtopathicity after 4 days of incubation and the virus titres were expressed as CCID S0 /mL. Anti-HIV assays. Activity of the compounds against HIV- 1 and HIV-2 multiplication in acutely infected cells was based on the inhibition of virus-induced cvtopathicity in MT-4 and C8166 cells, respectively. Briefly, 50 μL of culture medium containing lxlO 4 cells were added to each well of flat-bottom microtiter trays containing 50 μl of culture medium with or without various concentrations of the test compounds. Then 20 μL of an HIV suspension containing 100 CCID 5() were added. After a 4-day incubation at 37 °C, the number of viable cells was determined by the 3-(4,5-dimethylthiazol-l-yl)-2.5-diphenyltetrazolium bromide (MTT) method. Cytotoxicity of the compounds was evaluated in parallel with their antiviral activity. It was based on the viability of mock-infected cells, as monitored by the MTT method. RT assays. Assays were performed as follows. Briefly, purified rRT was assayed for its RNA-dependent polymerase-associated activity in a 50 μL volume containing: 50 mM TrisHCl (pH 7.8), 80 mM KCI1, 6mM MgC12, 1 mM DTT, 0.1 mg/ mL BSA, 0.3 OD 260 unit/mL templateφrimer [poly(rC)-oligo(dG)12-18] and 10 μM [ΗjdGTP (1 Ci/mmol). After incubation for 30 min at 37 °C, the samples were spotted on glass fiber filters (Whatman GF/A), and the acid-insoluble radioactivity was determined. EXAMPLES 2-Cyclopentylthio-6-f2.6-difluorophenylmethylV3.4-dihydrogyrimidin-4-(3H)-one (MC867). A mixture of 6-(2,6-difluorophenylmethyl)-1.2,3,4-tetrahydro-2-thiopyrimidin-4(3H)-one (0.16 g, 0.65 mmol; prepared as reported in scheme B), cyclopentyl bromide (0.11 g, 0.08 mL., 0.71 mmol) and potassium carbonate (0.09 g, 0.65 mmol) in 1 mL of anhydrous DMF was stirred at room temperature for 24 h. After treatment with cold water (200 mL), the solution was extracted with ethyl acetate (3 x 50 mL). The organic layers were collected, washed with brine (3 x 50 mL), dried and evaporated to furnish crude MC867, which was purified by chromatography on silica gel column (eluent: n-hexane/ethyl acetate/methanol 12/3/1). Yield (%): 45; mp (°C): 168-169; recrystallization solvent: cyclohexane; formula (molecula- weight): C lft H lft F,N,OS (322.37). 2-Cyclopenlylthio-6-(2.6-difluorophenylmethyl)-3.4-dihvdro-5-methylpyrimidin-4-(3HVone (MC922). The synthesis of MC922 was accomplished according to the above reported procedure starting from 6-(2,6-difluorophenylmethyl)-5-methyl- 1 ,2.3,4-tetrahydro-2-thiopyrimidin-4- (3H)-one (see scheme B). Yield (%): 54; mp (°C): 192-193; recrystallization solvent: cyclohexane; formula (molecular weight): C l7 H ls F 2 N,OS (336.40). 2-CyclopentyIthio-6-[l-(2.6-difluorophenyl)ethyl]-3,4-dihydropyrimidin-4-(3- t π-one fMC1008^ The synthesis of MC1008 was accomplished according to the above reported procedure starting from 6-[l-(2,6-difluorophenyl)ethyl]-l,2,3,4-tetrahydro-2-thiopyrimidin-4(3H)-one (see scheme B). Yield (%): 54; mp (°C): 165.5-166.5; recrystallization solvent: cyclohexane; formula (molecular weight): C 17 Η 18 F,N,OS (336.40). 2-Cyclopentylthio-6-[l-(2.6-difluorophenyl)ethyl]-3.4-dihydro-5-methylpyrimidin4(3H)-one (MCI 047) The synthesis of MC1047 was accomplished according to the above reported procedure, starting from 6-[l-(2,6-difluorophenyl)ethyl]-5-methyl-l,2,3,4-tetrahydro-2-thiopyrimidin- 4(3H)-one (see scheme B). Yield (%): 60; mp (°C): 196-197; recrystallization solvent: cyclohexane; formula (molecular weight): C 18 Η, (l F,N,OS (350.43). 6-(2.6-Difluorophenylmethyl)-3.4-dihydro-2-(methylthiomethyl)thiopyrimidin-4-(3H)-one (MC1161) The synthesis of MCI 161 was accomplished according to the above reported procedures, starting from 6-(2,6-difluorophenylmethyl)-l ,2,3,4-tetrahydro-2-thiopyrimidin-4(3H)-one (see scheme B) and chloromethyl methyl sulfide. Yield (%): 72; mp (°C): 159-160; recrystallization solvent: benzene/cyclohexane; formula (molecular weight): C 13 Η 12 F,N,OS, (314.37). 6-(2.6-Difluorophenylmethyl)-3.4-dihydro-5-methyl-2-(methylthiomethyl)thiopyrimidin- 4(3H)-one (MC1162). The synthesis of MCI 162 was accomplished according to the above reported procedure, starting from 6-(2,6-difluorophenylmethyl)-5-methyl- 1 ,2,3,4-tetrahydro-2-thiopyrimidin 4(3H)-one (see scheme B) and chloromethyl methyl sulfide. Yield (%): 70; mp (°C): 183-184; recrystallization solvent: benzene/cyclohexane; formula (molecular weight): C 14 Η 14 F,N,OS 2 (328.39). 6-(2.6-Difluorophenylmethyl)-3.4-dihydro-5-(l-methylethyl)-2-(methylthiomethyl) thiopyrimidin-4-f 3HVone MCI 145). The synthesis of MC1145 was accomplished accord iπg-to the above reported procedure, starting from 6-(2,6-difluorophenylmethyl)-5-(l-methylethyl)- 1 ,2,3,4-tetrahydro-2- thiopyrimidin-4(3H)-one (see scheme B) and chloromethyl methyl sulfide. Yield (%): 62; mp (°C): 158.5-160; recrystallization solvent: cyclohexane; formula (molecular weight): C 16 Η, 8 F 2 N,OS 2 (356.45). 2-Cyclopenltylamino-6-(2.6-difluorophenylmethylV3.4-dihydropyrimidin-4-(3H)-one (MC1022). Cyclopentvlamine (10 mL) was heated while stirring with 6-(2,6-difluorophenylmethyl)-3,4- dihydro-2-methylthiopyrimidin-4-(3H)-one (0.30 g, 1.12 mmol; prepared as reported in scheme B or C) in a sealed tube at 160°C for 10 h. After cooling, the mixture was diluted with water (200 mL) and extracted with ethyl acetate (3 x 50 mL). The organic layers were collected, washed with brine (3 x 50 mL), dried and evaporated to furnish crude MC1022, which was purified by chromatography on silica get column (eluent: ethyl acetate/chloroform 1/1). Yield (%): 74: mp (°C): - (oil); formula (molecular weight): C lft H I7 F 2 N 3 O (305.33). 2-Cyclopentylamino-6-(2.6-difluorophenylmethyl)-3.4-dihydro-5-methylpyrimidin-4-(3H)- one (MC1050). The synthesis of MC1050 was accomplished according to the above reported procedure, starting from 6-(2,6-difluorophenylmethyl)-3.4-dihydro-5-methyl-2-methylthiopyrimidirin- 4(3H)-one (see scheme B or C). Yield (%): 60: mp (°C): 115-117; recrystallization solvent: n-hexane/cyclohexane; formula (molecular weight): C 17 Η ιq F,N 3 O (319.35). 2-Cyclopentylamino-6-[l-r2.6-difluorophenyl)ethyl]-3.4-dihydropyrimidin-4-(3H)-one rMC1048V The synthesis of MCI 048 was accomplished according to the above reported procedure, starting from 6-[l-(2,6-difluorophenyl)ethyl]-3,4-dihydro-2-methylthiopyrimidin-4(3H)-one (see scheme B or C). Yield (%): 48; mp (°C): - (oil); formula (molecular weight) C 17 Η l9 F,N 3 O (319.35). 2-Cyclopentylamino-6-[l-(2.6-difluorophenyl)ethyl]-3.4-dihydro-5-methylpyrimidin-4-(3H)- one (MC1129) The synthesis of MCI 129 was accomplished according to the above reported procedure, starting from 6-[l-(2,6-difluorophenyl)ethyl]-3.4-dihydro-5-methyl-2-methylthiopyrimidin- 4(3H)-one (see scheme B or C). Yield (%): 38; mp (°C): - (oil); formula (molecular weight): C 18 Η 21 F,N 3 O (333.38). 6-(2.6-Difluorophenylmethyl)-3.4-dihydro-2-(4-thiomorpholin-l-yl)pyrimidin-4-(3H)-one CMC1193). The synthesis of MCI 193 was accomplished according to the above reported procedure, starting from thiomorpholine and 6-(2,6-difluorophenylmethyl)-3,4-dihydro-2- methylthiopyrimidin-4(3H)-one (see scheme B or C). Yield (%): 78; mp (°C): 233-234; recrystallization solvent: acetonitrile; formula (molecular weight): C 15 H,,F,N 3 OS (323.36). 6-(2.6-Difluorophenylmethyl)-3.4-dihydro-2-NJV-dimethylaminopyrimidin-4-(3H)-one (MCI 182). To a stirred solution of sodium metal (0.14 g, 6.3 mg-atoms) in absolute ethanol (50 mL) 1,1- dimethylguanidine sulfate (1.17 g, 4.3 mmol) and ethy! 4-(2,6-difluorophenyl)acetylacetate (0.76 g, 3.15 mmol) were successively added. The mixture was heated while stirring at reflux for 8 h. After cooling, the solvent was distilled in vacuo at 40-50°C until dryness and the residue was dissolved in water (200 mL) and made acid (pΗ 5) with 0.5Ν acetic acid. The resulting precipitate (the crude isocytosine derivative) was filtered under reduced pressure, washed with diethyl ether, vacuum dried at 80°C for 12 h and then crystallized from benzene/cyclohexane (see scheme C starting from ethyl 4-(2,6-difluorophenyl)acetylacetate and replacing guanidine hydrochloride with 1,1-dimethylguanidine sulfate). Yield (%): 88; mp (°C): 210-211; recrystallization solvent: benzene/cyclohexane; formula (molecular weight): C 13 Η 13 F,N 3 O (265.26). Table 1. Physical and Chemical Data of MC Compounds Conip . X Y z R R' R 2 IV IV R 5 ill. p., ° C Recryst Solvent % yield Formula " MC 5 07 0 H 11 2,5-Me 2 -c-hex H 11 II II H 130-132 Petrol. Ether/dielliyl ether 22 C„H, 4 NA MC 5 08 () It 11 4,5-Me 2 -c-hex 11 11 11 II 11 132-134 Petrol. El er/diethyl ether 28 C,,H, 4 N 2 0 2 MC 5 1 2 () II II 3,5-Me 2 -c-hex 11 11 11 H II 178-181 Petrol. Ether/dielhyl ether 12 C„H, 4 N 2 0, MC 5 1 o Me H 2,5-Me 2 -c-hex H 11 H H 11 196-198 Petrol. Elher/diethyl ether 18 C„H 2f ,N 0, MC 1114 0 11 11 See-but F 11 11 II F 87-88 Petrol Ether/dielhyl ether 28 C„II,„F,N,(), MC 1103 C) II 11 e-peπt F 11 11 11 F 183.5-1845 Benzene 52 C-,„II, ',N,(), MC8 3 s II II beiizyloxyniclh II 11 II 11 11 181-183 Cytoheλ.ine/bei ene 38 e„n, » N 2 o,s MC 796 s 11 I'll Sec-bul H H 11 11 11 157-158 n-hexane/cyelohex.ine 78 C,,II,,N,OS MC 890 s 11 Me Iso-prop 11 11 II 11 H 118-119 n-hexane 88 C, 5 M, a N,()S MC 892 s II Me c-pent II 11 11 II H 95-96 n-hexane 65 C', 7 H,„N,OS MC 898 s II Me t-liex 11 11 11 11 11 142-143 n-hexane 59 C,»H 2 .N 2 C)S MC 899 s 11 El lso-prop II II 11 11 H 144-145 Cyclohexane 85 C,„ll 2 „N,OS MC 900 s 11 El c-pent 11 11 11 11 II 168-169 Cyclohexane 69 C IB I1 2 ,N 2 ()S M 903 s 11 El e-hex 11 11 11 II H 175.5-176.5 Cyclohexane 60 ( ■ „II, N,OS MC 806 s 11 11 See-but Me 11 11 II 11 118-119 n-liexant/cyclohexane 67 C„,H,„N 2 OS MC 842 s II 11 c-pent Me H II II 11 142-144 Cyclohexane 61 C' l7 II,„N OS MC809 s H 11 See-but H 11 Me H 11 107.5-108.5 n-hexane 56 C„,II 2ll NOS MC817 s H 11 Sec-bul NO, II 11 II II 148.0-148.5 Cyclohexane/bcn eiie 68 C 1S 1I„N,0,S MC 897 s 11 II See-but II NO, II II II 127-128 Cyclohcxane/beii enc 54 C- |s ll„N, ,S MC 863 s 11 II See-but 11 II N() 2 H II 128-130 Petrol. Ether/dielhyl ether 100 C 15 H, 7 N 3 0 3 S MC 8 5 4 s H 11 See-but Cl H H H H 120-121 n-hexane/cyclohexane 58 C 15 II, 7 N 3 0,S MC8 5 7 s II 11 Sec-bul 11 Cl 11 II 11 98-99 Cyclohexane 92 C„ll„N,0,S MC 8S9 s H II See-but H H l II 11 125-126 Cyclohexane 74 C„1I„CIN 2 ()S MC 880 s II 11 Sec-bul I'II II II II 106-107 n-hexane/cyclohexane 68 MC884 s 11 II See-but ll F 11 H H 96-97 Cyclohexane 67 MC 889 s 11 II See-but II II I'II 11 98-99 n-hexane 94 C„1I|,FN,( ) S MC 825 s II II See-but Nil, II ll 11 II 143-144 Cyclohexane/ben enc 74 C^II^N.OS MC 960 s 11 11 Sec-bul II II Nil, 11 II 128- 130 Cyclohexane 77 C ls ll„Nj()S MC 868 s II 11 Sec-bul Cl- II II II II 125-126 Cyclohexane 89 C| ( .H I7 F,N,()S MC 959 s 11 11 See-but 11 II C'F, 11 11 144-145 Cyclohexane 75 C„1I W F,N,()S MC 952 s 11 11 See-but OMc II II II II 123-124 Cyclohexane 69 '. I^N.O.S Table 1. Physical and Chemical Data of MC C'ompounds (continued) Compl. X Y Z l< R 1 R- in. p., ° C Recrysl. Solvent % yield I ' ornuila " MC 957 S 11 Sec-bul II OMc II 11 11 78-80 n-licxiiiie/ Cyclohexane 71 C ' „,IL„N,(),.S MC 964 s II See-but II 11 OMe 11 11 112-113 Cyclohexane 63 C 1 „ll,„N,0,S MC 1041 s 11 See-but II F 11 II 11 122-123 Cyclohexane 68 C 1S H„,F 2 NAS MC 1042 s II Sec-bul II Me II II 11 119-120 n-hexane 72 C, 7 ll„N,OS MC877 s II Me Cl 11 II 11 Cl 237-238 benzene 98 C,,II,„C:I,N,OS MC878 s II i.so-prop Cl 11 11 11 Cl 230-231 benzene 81 C, H 14 CI,N,0S MC886 s H n-but Cl 11 11 11 Cl 153-154 cyclohexane 62 C, 5 H„ t CI,N 2 OS MC885 s 11 iso-but Cl 11 II II Cl 143.5-144.5 cyclohexane 56 C, ll,„CI,N,OS MC815 s 11 sec-bul Cl 11 11 11 Cl 183-184 eyclohexane/benzene 55 C„1I„,C1 N 2 0S MC888 s II c-penl Cl 11 II II Cl 185-186 cyclohexane 54 C 1 „I1„,CI 2 N,()S MC89I s 11 c-hex Cl 11 II 11 Cl 200-201 cyclohcxane/benzene 49 C, 7 ll,„CI,N, S MC871 s 11 Me F 11 11 II F 197-198 benzene 95 C l2 ll„,F,N,OS MC860 s H iso-prop F 11 11 II F 174-175 cyclohexane 74 C, 4 ll, 4 FN 2 OS MC872 s 11 n-but F 11 11 11 F 126-127 cyclohexane 46 C l5 H„F,N, S MC866 s H iso-but F 11 11 11 F 136-137 cyclohexane 49 C,,H„F,N,OS MC848 s II see-but F II II 11 F 149-150 n-hexane/cyclohexane 48 C| 5 M„,F,N,OS MC867 s H c-pent F II 11 II F 168-169 cyclohexane 45 C, 6 ll,„FN,OS MC870 s H c-hex F 11 11 H F 164-165 cyclohexane 40 C,-,lt ls F,N,OS MC100I s H Me i.so-prop l II n 11 Cl 196-196.5 eyclohexane/benzene 52 C„Il„,CI,N, S MC996 s H Me c-pcnt l H 11 II Cl 181-182 cyclohexane 45 c: l7 n, s cι,N,os MC1016 s H Me c-hex Cl 11 H 11 Cl 211-212 eyclohexane/benzene 42 C, X H20CI,N, S MCI 000 s 11 El iso-prop Cl 11 11 II Cl 166-168 dielhyl ether 54 C16H IB Cl 2 N,OS MC1002 s 11 El c-penl Cl 11 11 11 l 168-169 diethyl ether 40 C I8 H 2 »U,N,OS MCI 003 s II Et c-hex Cl 11 11 II Cl 198-199 cyclohexane 41 c, v n, 2C "i.N,os M I 007 s 11 Me iso-prop F 11 11 II F 155-156 cyclohexane 53 C„ll 1Λ F,N, S M I 044 s 11 Me iso-but F 11 11 II F 159-160 cyclohexane 49 C lh M l ,F,N,OS MCI 045 s 11 Me n-bul F 11 11 H F 149-150 cyclohexane 58 c: l „ιι,„F 2 N,os MCI 110 s 11 Me see-but F 11 II 11 F 133-134 n-hexane 75 C,„ll IK F 2 N, S M I 008 s H Me c-pent F II 11 11 F 165.5-166.5 cyclohexane 60 t l7 ll ls F,N, S MCI 013 s 11 Me c-hex F 11 II H F 206-207 benzene 44 C„,H,„F,N,0S MCI 005 s 11 Et iso-prop F 11 II 11 F 149-150 cyclohexane 40 C„,H,»FN 2 S M I 006 s II Et c-penl F 11 II 11 F 141-143 cyclohexane 45 C 111 1I,„F 2 N, () S MC1014 s 11 Et c-hex F 11 11 H F 154-155 cyclohexane 51 C„ll 22 F,N, S MC971 s 11 Me iso-prop CH=CII-CH=CII 11 H H 161-162 n-hexane/cyclohexane 58 C, H 211 N,OS MC972 s II Me c-pent cn=cn-cn=cιι II II 11 140-141 n-hexane/cyclohexane 49 C,,II,,N.( ) S MC974 s H Me c-hex CH=CH-CH=CII 11 11 11 177-178 n-hexane 45 C,,H, 4 N 2 OS MC969 s 11 Et iso-prop CH=CH-CH=CH H H 11 163-164 cyclohexane 54 C 2 „lI,,N 2 OS MC973 s 11 Et c-pent CH=CII-CII=CI1 II II H oil - 48 C„ll 24 N OS MC975 s 11 El c-hex cn=cιi-cιι=CH II 11 11 126-127 n-hexane 41 C,,H, h N,OS MC844 s Me II see-but Me II 11 11 11 177-178 cyclohexane 55 C„ll 2 ,N,OS MC845 s Me 11 see-but H II Me H 11 127-128 n-hexane 61 C, 7 II,,N 2 OS MC925 s Me H see-but II NO, H H II 163-164 eyclohexane/benzene 88 C, 6 1I, N 3 O J S MC924 s Me 11 sec-bul 11 H NO, II H 178-180 eyclohexane/benzene 100 MC909 s Me II sec-bul Cl II II II II 170-171 cyclohexane 68 C,„II,„C:IN 2 C)S Table 1. Physical and Chemical Data of MC Compounds (continued) Compd. R 1 R- R' iV m. p., ° C Recrysl. Solvent "A- yield Formula MC9I0 S Me II sec-bul II Cl 11 II 11 145-146 cyclohexane 75 C I( JI,„CIN,()S MC91I S Me 11 sec-bul 11 II Cl II II 163-165 cyclohexane 79 MC 13 S Me II sec-bul I'II II II H 120.5-121.5 cycloliexane 65 MC9I S Me 11 sec-bul ll I' ¬ I'11 II 146-147 cyclohexane 72 C,„ll l . ) FN,OS MC 1 S Me 11 sec-bul II ll ll 11 II 154-155 cyclohexane 69 C,„ll,.,FN,OS MC9I2 S Me 11 Me Cl II 11 11 l 206-261 benzene 93 C,,ll l ,C , l,N,OS MC9I4 S Me 11 iso-prop Cl 11 11 11 Cl 241-242 eyclohexane/benzene 78 C: l5 H„,C'l 2 N, S MC:920 S Me II n-bul Cl 11 II 11 Cl 179-180 cyclohexane 52 C„JI IS CI 2 N, () S MC9I6 S Me 11 iso-bul l 11 II 11 Cl 208-209 cycloliexane 63 c: l „ιι„ l cι,N,os MC850 S Me 11 see-but Cl 11 II 11 Cl 204-205 cyclohexane 53 C„ 1 H I8 CI 2 N 2 ()S MC 15 S Me 11 c-pent Cl 11 11 11 Cl 252-253 eyclohexane/benzene 49 C„ll 1B CI 2 N 2 OS MC9I7 S Me II c-hex Cl II 11 11 Cl 237-238 cyclohexane 48 C,„ll,„CI 2 N,OS MC869 S Me II Me F II 11 II F 218.5-219.5 benzene 92 C l3 ll,,F,N 2 OS MC881 S Me II iso-prop F 11 11 11 F 164-165 cyclohexane 76 < : ι . llι„l ; 2 S MC905 S Me II n-but F II 11 11 F 178-179 cyclohexane 65 C.JI^FAO MC921 S Me 11 iso-but F 11 11 II F 161-162 cyclohexane 59 ) C,„lI,„F,N.OS MC849 S Me 11 sec-bul F II 11 II F 128-129 n-hexane 49 C,„ll l8 F,N S MC:922 s Me 11 c-penl F 11 II II F 192-193 cyclo exane 54 C„H 18 F,N,OS MC:923 s Me 11 c-hex F 11 II 11 F 191-192 cyclo exane 49 ,«ll 2 „F,N, S MCI 060 s Me Me Me F II 11 11 F 202-203 eyclohexane/benzene 49 C l4 !l l4 F,N,OS MCI 109 s Me Me see-but F 11 II 11 F 135-136 cyclohexane 55 C,,II,„FN S M I 047 s Me Me c-pent F II 11 II F 196-197 cyclohexane 60 C,„ll 211 F 2 N, S MC798 s El 11 see-but II II 11 II H 140-141 n-hexane 47 C, 7 H 22 N,OS MCI 0.37 s Et 11 iso-prop F II 11 11 F 174-175 benzene 78 C„,H„F,N 2 S MC1038 s Et 11 see-but F H II H I'150-151 n-hexane/cyclohexane 62 C, 7 H ; „F,N,()S MC804 s El 11 see-but CH=CII-CII=CII 11 11 ll 198.5-199.5 cyclohexane 42 C 2l ll_, 4 N, S MCI 039 s i-pro 11 iso-prop F 11 11 11 F 167-168 n-hexane 76 f - ' i-lt; ' 7 .' N 2 S MC852 s allyl II see-but II 11 11 II 11 127.5-128.5 cyclohexane 68 C„.H 2 ,N 2 S MC856 s n-pro 11 see-but 11 11 II 11 11 108-109 n-hexane 42 C ls ll, 4 N,OS MC834 s n-bul 11 see-but II 11 11 11 H oil - 32 C.„ll,„N,OS MCI 119 Nil II 11 ethyl F 11 11 π F 138-140 n-hexanc/cyclohcxane 50 C.ill. '.NiO MCI 078 N l 11 11 n-prop F 11 II II F 136-137 cyclohexane 49 C l H, s F,N,0 MC97 Nil 11 11 iso-prop F 11 11 H F 150-151 dielhyl ether 58 C, H„F,N,() MC980 Nil II H c-prop F II 11 H F 183-184 eyclohexane/benzene 68 C l4 H„F 2 N,0 MCI 077 Nil II II n-bul F 11 11 II F 130-131 n-hexane 60 C 1 H, 7 F 2 N,0 MC945 Nil H 11 sec-bul F 11 11 H F 140-141 dielhyl elher 80 C:„H 17 F,N 3 O MCI043 Nil II H MeOelh; F 11 II II F 120-121 acelonitrile 78 C l4 H„F,N 3 0, MCI 022 NH 11 11 c-penl F H 11 II F oil - 74 C l „H„F 2 N . ,0 MC1049 Nil 11 II c-hex F 11 11 11 F 143-144 diet yl ether 45 C, 7 H I „FN,0 MCI 048 Nil II Me c-penl F II 11 II F oil - 48 C, 7 1I„F2N,0 MCI 118 Nil Me II iso-prop F 11 11 II F 165-166 n-hexane 53 C 15 I1 I7 F,N 3 0 MCI 130 NH Me 11 see-but F 11 It II F oil - 56 C l „H,„F 2 N 3 0 MCI 050 NH Me II e-penl F 11 H H F 115-117 n-hexane/cyclohexane 60 C, 7 H„F,N . ,0 MCI 105 NH Me H benzyl F II 11 11 F 182-183 eyclohexane/benzene 82 C,.,I1 17 F 2 N 3 0 Table 1. Physical and Chemical Data ol MC Compounds (continued) Conipd Y Z R iV m p ° C Recrysl SoKcnl '/, yield Horniul i MC 1129 Nil Mc Mc c pcnl 1 11 II II I oil 3b C ,„I1 ,1 N,() MCI 167 Nil II II Mc 1 II 11 11 r 202203 iccloiiilrilc 39 C H,,Γ N,O MC1168 Nil Me II Mc r 11 11 H F 210211 icclonilnlc 48 C M II„ΓN,O M I 186 NH Mc II n prop F 11 II II F 156157 acclonitπle 62 C, 11, I,N,() MCI 185 Nil Me II n but F 11 H 11 F 192193 acclonilπlc 68 c„n,,r N,O MC 1178 NH II Mc Mc r 11 11 H F 145 146 acctoniliile 34 C„II π I N,C) MC 1190 Nil 11 Me n prop F 11 11 11 F oil 45 C„H, 7 F,N,0 MC 1191 Nil 11 Mc lso prop I II 11 II r oil 54 C„II, 7 l N,( ) MCI 189 NH 11 Mc n but I 11 11 II F oil 55 C, I, 7 FN 3 0 MCI 192 NH 11 Me sec bul t- 11 II 11 I oil 59 C„II„FN,0 MCI 180 Nil II Me c hex r 11 11 II F oil 62 CH ,I 2 N,C> MCI 170 Nil Mc Mc Mc r 11 11 11 F 193194 cyclohcx inc/bcnzcnc 34 C, 4 H„l,N 3 0 MCI 187 Nil Mc Mc n but r 11 11 II F oil 49 C I7 H ,Γ,N,O MC 1181 Nil Mc Me c hex Γ 11 11 11 r oil 54 C„H„F 2 N,0 MCI 182 N H H Me 2 F II 11 H Γ 210211 cyclohexanc/bciizcnc 88 C,,H„F,N,0 O ) MCI 183 N 11 H Mt pipcraz r 11 11 H F 195196 acelonilπlc 84 C„Hι»F,N 4 0 MCI 188 N 11 II πiorph F 11 II 11 F 215216 icctonitiilc 75 C„H„Γ N A MCI 193 N 11 11 t ioinorph r 11 II 11 F 233234 icclonilnlc 78 C „H„I N,()S MCI 194 N n 11 pipeπd r 11 11 H F 209210 icclonitπle 68 C„H, 7 F N,() MCI 196 N 11 11 pyrrolid r 11 11 11 F 233234 acclonilrilc 52 C,,H„F,NjO ) M I 202 N II 11 Et 1 11 II 11 F 159160 acclonilπlc 43 C„U17F,N,() M I 204 N 11 H (n prop), r 11 II 11 F 111 112 n hcxanc 32 C , 7 H,,F,N 3 0 MCI 195 N Me 11 Me 2 r 11 11 H F 237238 acclonitπlc 80 C I4 H„F 2 N 3 C) i MC 1203 N Mc 11 Me piper iz r 11 II H F 235236 icclonilnlc 62 c,,n ,Γ,N 4 O MC1205 N Mc II morp F 11 11 11 r 244245 icclonilnlc 65 C.,11,,1 N,0 MC1206 N Me 11 thioinorph 1 11 II 11 I 255256 icclonilnlc 54 C„ll l7 [ N, S MC 1137 S Mc Mc iso prop r 11 11 II 1 177178 n hex inc/cyclohcx mc 45 C „II,„I N OS M I 175 S Mc Me n bul r 11 11 II F 122123 n hex mc 51 C ,,11 „l N OS MCI 153 s Me Mc iso bul r 11 II II r 152153 cyclohcx inc 58 C, 7 H„I,N OS MCI 174 s Mc Mc c hex F 11 II 11 r 208209 n hex lnc/cyelohcxanc 48 C lv H r N OS MC1161 s 11 11 MeSMe F H H H F 159160 cyclohcx inc/benzcnc 72 C, 3 H,,F,N OS MCI 162 s Mc II McSMe F 11 II H F 183184 cyclohcx inc/bcnzenc 70 C, 4 II, 4 Γ,N 2 OS MCI 157 s Et H MeSMe F H 11 H F 153154 cyclohexane 69 C, 5 H„,Γ,N,OS MCI 145 s i pro 11 MeSMe r 11 11 11 F 1585160 cyclohex ine 62 C„H,»F,N,OS MCI 140 s H H McSMe H 11 II H 11 1175118 n hexane 64 C 13 H, 4 N 2 s, 'All compounds were analyzed for C, H, N, S, and, when required, Cl and F, analytical results were within ±04% of theroretical values Table 2. Cytotoxicity and anti-I IlV- 1 Activity of MC Compounds. Compd. Y R 2 R Λ R 5 MC 507 O H 2,5-Me,-c-hex II 143 3.5 40 MC 508 O H 4,5-Me 2 -c-hex H 58 6.4 9 MC 512 O II 3,5-Me 2 -c-hcx II >20() 30 >6.7 MC 531 O Mc 2,5-Me 2 -c-hex II 138 3.5 39 MC 11 14 O II see-but F 130 25 52 MC 1103 O II c-pcnt F >2()0 20 >10 MC 843 S 11 benzoyloxymcthyl II >20() 45 >4 MC 796 S II Ph see-but II 61 >61 MC 890 S H Me iso-prop II >200 .9 >222 MC 892 S H Me c-pent H 159 .6 333 MC 898 S H Me c-hcx II 149 .6 248 MC 899 S H Ei iso-prop II 200 .8 250 MC 900 S II E c-pcnt H >200 1.0 >20() MC 903 S II Ei c-hex H >20() 1.3 >154 MC 06 s II see-but Me >200 1.8 > U 1 MC 842 s II c-pent Me >200 3.4 >59 MC 809 s II see-but II Mc 200 0.6 333.3 MC 817 s H see-but NO, >200 0.25 >800 MC 897 s H see-but II NO, 157 0.40 392 MC 863 s II H see-but H NO, 151 1.5 101 MC 854 s II see-but Cl 200 1 200 MC 857 s II see-but II 116 2 58 MC 859 s II see-but H 120 5 24 MC 880 s II scc-but F 200 0.26 769 MC 884 s II see-but H >200 0.7 >286 MC 889 s II scc-but II >20() 8.7 23 MC 825 s II scc-but NH 2 >200 21.2 >9 MC 960 s II scc-but II Ni l, >200 23 >8 Table 2. Cytotoxicity and anti-IIIV-1 Activity of MC Compounds (continued) Compd. X Y Z R R' R- iv R 4 SI MC 868 S 11 sec-bul CF, II II II 11 >200 32 6.2 MC 959 S II see-but II II CF, II II 200 25 8 MC 952 S II scc-but OMc II 11 II II >200 1.96 >208 MC 957 S 11 see-but II OMc II II II >200 1.2 >166 MC 964 s II see-but II II OMc II II 147 14 10.5 MC 1041 s II sec-bul 11 F II F II >200 1.4 >143 MC 1042 s II see-but II Me II Mc II 133 0.6 222 MC 877 s II Me Cl II π 11 Cl >200 3.2 >62 MC878 s 11 iso-prop Cl II 11 II Cl >200 1.9 >105 MC886 s H n-but Cl II II II Cl >200 0.44 >454 MC885 s H iso-but Cl H II II Cl >2()0 0.45 >444 MC815 s H see-but Cl II II 11 Cl >2()() 0.14 > 1,428 MC888 s 11 c-pcnt Cl II II II Cl >2 ( K ) 0.4 >500 ? MC891 s II c-hcx Cl II 11 II Cl >200 0.6 >333 MC871 s II Me F II II 11 F 200 0.81 247 MC 860 s II iso-prop F II II II F >200 0.2 > 1,000 MC872 s II n-but F 11 II II F 162 0.18 900 MC 866 s II iso-but F II 11 11 F 182 0.14 1,300 MC 48 s II scc-but F 11 II II F 200 0.04 5,000 MC 867 s II c-pent F 11 II 11 F >200 0.08 >2,500 MC870 s II c-hex F II II II F 200 0.08 2,500 MC 1001 s H Me iso-prop Cl 11 II II Cl 117 1.2 97.5 > MC 996 s II Me c-pcnt Cl II II II Cl 78.3 1.0 78.3 MC1016 s II Me c-hcx Cl H II 11 Cl >200 2.9 >69 MC 1000 s II Et iso-prop Cl H 11 II Cl >200 0.4 >5()() MC 1002 s 11 Et c-pent Cl II II II Cl 23.4 1.0 23.4 MC 1003 s II Et c-hcx Cl H II II Cl >200 3.6 >55.5 MC 1007 s II Me iso-prop F II 11 II F 167 0.05 3,340 MC 1044 s II Mc iso-but F 11 II II F >2 ()() 0.05 >4,000 MC 1045 s 11 Me n-but F II II II F >200 0.07 2,857 MC 1110 s 11 Me see-but F II II 11 F >2()0 0.03 >6,666 MC 1008 s II Me c-pcnt F II II 11 F >200 0.03 >6,666 MC 1013 s 11 Me c-hex F II 11 11 F >200 0.16 > 1,250 MC 1005 s II Et iso-prop F 11 II II F 70 0.08 875 MC 1006 s II Et c-pent F II II II F 200 0.15 1,333 Table 2. Cytotoxicily and anti-IIIV-1 Activity of MC Compounds (continued) Compd X Y iv IV R' [μM] SI'' C- ' • HC ,' MC 1014 S II El c-hex F II F 130 0.05 2,600 MC971 S II Me iso-prop CII= CII-CII=CII II 119 1.1 108 MC 972 s 11 Mc c-pcnt CII= CII-CII=CII II 93 0.5 186 MC 974 s II Me c-hex CH= cn-cιι=cιι II 45 0.14 321.4 MC 969 s H Et iso-prop CH= CII-CH=CH II 50 1.5 33.3 MC 973 s II Et c-pcnt CII= CII-CII=CH II 51 3.0 17 MC 975 s II Et c-hex CH= CH-CII=CII II 16.9 0.18 94 MC844 s Me scc-but Mc II >200 1.7 >U8 MC845 s Me scc-but II Mc 11 26 0.8 32 MC 925 s Me scc-but 11 NO, II II >200 0.35 >571 MC 924 s Me scc-but II NO, II >200 2 >100 MC 909 s Me see-but Cl 11 >200 0.27 >741 MC910 s Me scc-but 11 Cl II >200 0.96 >208 1 MC911 s Mc scc-but II 11 >200 9.5 20 MC 13 s Me scc-but F 11 140 0.41 341 MC918 s Me see-but II II >200 1.2 >166 MC919 s Me scc-but 11 II 105 11 9.5 MC912 s Me Mc Cl Cl >20() 3.2 >62 MC914 s Mc iso-prop Cl Cl >200 1.3 >154 MC 920 s Mc n-but Cl Cl >2()0' 1.17 >171 MC916 s Me iso-but Cl Cl >200 1.2 >166 MC 850 s Me scc-but Cl Cl >2(KI 0.05 >4,000 MC915 s Me c-pcnt Cl Cl >200 1.8 >111 MC917 s Me c-hcx Cl Cl >200 22 >9 MC 869 s Mc Me F F 200 0.19 1,053 MC 8 1 s Mc iso-prop F F >200 0.05 >4,000 MC 905 s Me n-but F F >200 0.08 >2,5()() MC921 s Me iso-but F F 64 0.1 640 MC849 s Mc scc-but F F 80 0.001 8,000 MC 922 s Me c-pent F F >200 0.08 >2,500 MC 923 s Me c-hcx F F >200 0.09 >2,222 MC 1060 s Me Me Me F I- >200 0.04 >5,000 MC 1109 s Mc Me scc-but F F 200 0.03 6,666 MC 1047 s Mc Me c-pent F F >200 0.009 >22,222 MC 798 s Et II scc-but 11 II >2()() 1.0 >200 Table 2. Cytotoxicity and anti-IIIV-1 Activity of MC Compounds (continued) Compd. X Y Z R R' R 2 ιr [μMl SI'' BCV MC 1037 s Et II iso-prop F II II II F 65 0.2 326 MC 1038 s Et II scc-but F II 11 II F >200 0.1 >2,000 MC: 804 s Et II scc-but CH=CII-CII= =CII 11 II II >2()0 5.3 >34 MC 1039 s iso-piop 11 iso-prop F II 11 II F >200 0.4 >500 MC 852 s allyl II scc-but 11 II II 11 II >200 3 >67 MC 856 s n-prop 11 scc-but II II 11 II II 190 12 16 MC834 s n-but II see-but II II II II H >20() >200 MCI 119 NH H H ethyl F II II II F >200 0.8 >250 MC 1078 NH H H n-prop F II II II F 200 0.11 1,818 MC 979 NH II H iso-prop F II II II F >200 0.38 >526 MC 980 NH II H c-prop F II 11 II F >200 3.17 >63 MC 1077 NH H H n-but F II H II F 100 0.10 1,000 MC 945 NH II II see-but F II II II F >200 0.13 > 1,540 MC 1043 NH H H McOethyl F II II II F >200 0.8 >25() MC 1022 NH II II c-pcnt F II H H F >200 0.09 >2,222 MC 1049 NH H 11 c-hex F H 11 H F 66 0.14 471 MC 1048 NH II Me c-pcnt F H II H F 75 0.03 2,500 MCI 118 NH Me II iso-prop F H II II F 190 0.03 6,333 MC 1130 NH Me H scc-but F II II II F 200 0.07 2,857 MC 1050 Nil Me II c-pcnt F H 11 11 F >200 0.02 > 10,000 MC 1105 NH Me II benzyl F II II II F 50 0.50 100 MC 1129 NH Mc II c-pent F II II 11 F 90 0.02 4,500 MC 1167 NH 11 11 Me F 11 II II F >200 1.5 >133 MC 1168 NH Me H Me F H II 11 F 135 0.4 335 MC 1186 NH Me II n-prop F II 11 II F >200 0.02 > 10,000 MC 1185 Nil Mc II n-but F II 11 H F >200 0.02 > 10,000 MCI 178 NH II Me Me F II II II F 106 0.11 964 MC 1190 NH II Mc n-prop F II II 11 F 103 0.02 5,150 MC 1191 NH II Mc iso-prop F II II II F 115 0.03 3,830 MC 1189 NH II Me n-but F II H H F 52 0.03 1,730 MC 1192 NH H Mc scc-but F 11 H H F 86 0.04 2,150 MC 1180 NH H Mc c-hcx F II II II F 56 0.02 2,545 MC 1170 NH Me Me Me F H H II F 200 0.03 >6,666 MC1187 NH Me Me n-but F II II 11 F 83 0.01 8,300 MC1181 NH Me Me c-hcx F II II H F 58 0.03 2,231 Table 2. Cytotoxicity and anti-HIV-1 Activity of MC Compounds (continued) Compd. X Y Z R R 1 R 2 R' R s [μMl sr CC ' • IiCV MC 1182 N Mc, II 11 F >200 0.05 >4,0()() MC 1183 N Mc-piperaz II II F >200 7.1 >28 MC 1188 N morph F H II F >200 0.6 >333 MC 1193 N thiomoiph F II 11 F >200 0.05 >4,()00 MC 1194 N pipcrid F 11 II F >200 0.02 > 10,000 MC 1196 N pyrrol id F II II F >200 2.1 >95 MC 1202 N Et, F II II F >2()0 0.26 >769 MC 1204 N (n-prop). F II II F >200 3.8 >53 MC1195 N Me Me, F II II F >20() 0.02 > 10,000 MC 1203 N Mc Mc-pipcraz F II II F >200 0.36 >555 MC 1205 N Mc morph F II II F >200 0.047 >4,255 MC 1206 N Me H thiomorph F II 11 F >2()() 0.09 >2,222 MC1137 S Me Me iso-prop F II II F 200 0.007 28,571 . MC1175 s Mc Me n-but F II 11 F 112 0.008 14,000 MC 1153 s Me Me iso-but F II 11 F >2()0 0.01 >20,000 MC1174 s Me Mc c-hex F II II F >20() 0.018 >11,111 MC 1047+ s Mc Mc c-pent F 11 II F >200 0.002 > 100,000 MC 1047- s Me Me c-pent F II II F >200 0.7 >286 MC 1161 s II McSMe F II II F >200 0.80 >25() MC 1162 s Mc McSMe F 11 11 F 30 0.12 250 MC 1157 s Et MeSMe F 11 II F 50 0.11 454 MCI 145 s iso-prop McSMe F II 11 F 200 0.10 2,000 MCI 140 s II McSMe II II 11 II >200 20 >10 " Data represent mean values of at least two separate experiments. '' Compound dose required to reduce the viability of mock-infected cells by 50%, as determined by the MMT method. ' Compound dose required to achieve 50% protection of MT-4 cells from I II - 1 induced cytopathogcnicity, as determined by the MTT method. '' Selectivity index, CC 5( /EC ,„ ratio.

Claims: WHAT S CLAIMED IS: A compound of the formula: wherein: X is -0, -CH 2 , -CHK (wherein K is -H, -C^alkyl, -C 3.6 cycloalkyl ), -S, -NK (wherein K is -H, -C, .4 alkyl, -C 3 . ή cycloalkyl ), -aryl, -arylalkyl; R is -H, -C, .4 alkyl (containing one or more of heteroatoms like O, S, N), -C 3.h cycloalkyl (containing one or more of heteroatoms like O, S, N), -aryl, arylalkyl, heterocycle; Y is -H, -C,. 4 alkyl, -C 3 . 6 cycloalkyl; Z is -H, -C1 .4 a.kyl, -C 3 . 6 cycloalkyl; R, is -H, -C, .4 alkyl, halogen, -NO 2 , -OW (wherein W is -H, -CH 3 , -aryl), -SW (wherein W is -H, -CH 3 , -aryl); R, is -H, -C 1.4 alkyl, -halogen, -NO,, -OW (wherein W is -H, -CH 3 , -aryl), -SW (wherein W is -H, -CH 3 , -aryl); R, is -H, -C, .4 alkyl, -halogen, -NO,, -OW (wherein W is -H, -CH 3 , aryl), -SW (wherein W is -H, -CH 3 , -aryl); R is -H, -C, .4 alkyl, -halogen, -NO,, -OW (wherein W is -H, -CH 3 , -aryl), -SW (wherein W is -H, -CH 3 , -aryl); R, is -H, -C, .4 alkyl, -halogen, -NO,, -OW (wherein W is -H, -CH 3 , -aryl), -SW (wherein W is -H, -CH 3 , -aryl), or a pharmaceutically acceptable salt or soluble derivative thereof. 2. A compound having formula A as claimed in claim 1 wherein χ = 0 Y = H Z = H R = sBu R, = F R, = H [ R 3 = H R 4 = H R,= F X = 0 Y = H Z = H R = cPen R, = F R, = H [ R = H R 4 = H R~F. 3. A compound having formula A as claimed in claim 1 wheerreeiinn X = S Y = H Z = H R = X = S Y = H Z = H R = sBu R, = F R : = H R, = H R 4 = H R,=H X = S Y = H Z = H R = CH 3 R, = Cl R, = H R, = H R 4 = H R,=C1 X = S Y = H Z = H R = zpr R, = Cl R, = H R 3 = H R = H R,- = Cl X = S Y = H Z = H R = ;ιBu R, = Cl R, = H R, = H R = H R, = C1 X = S Y = H Z = H R = iBu R, = Cl R, = H R, = H R 4 = H R, = C1 X = S Y = H Z = H R = sBu R, = Cl R, = H R, = H R 4 = H R, = C1 X = S Y = H Z = H R = cPen R, = Cl R, = H R, = H R 4 = H R, = Cl X = S Y = H Z = H R = cEs R, = C1 R : = H R 3 = H R = H R, = C1 X = S Y = H Z = H R = CH 3 R, = F R, = H R 3 = H R 4 = H R, = F X = S Y = H Z = H R = ;Pr R, = F R, = H R 3 = H R = H R, = F X = S Y = H Z = H R = «Bu R 1 = F R, = H R 3 = H R 4 = H R, = F X = S Y = H Z = H R = iBu R, = F R, = H R 3 = H R 4 = H R, = F X = S Y = H Z = H R = sBu R, = F R 2 = H R 3 = H R 4 = H R 5 = F X = S Y = H Z = H R = cPen R, = F R, = H R 3 = H R 4 = H R = F X = S Y = H Z = H R = cEs R, = F R, = H R 3 = H R = H R ; = F X = S Y = H Z = CH 3 R = (Pr R, = Cl R, = H R, = H R 4 = H R, = Cl X = S Y = H Z = CH 3 R = cPen R, = Cl R, = H R 3 = H R 4 = H R, = Cl X = S Y = H Z = CH 3 R = cEs R, = Cl R, = H R 3 = H R 4 = H R, = Cl X = S Y = H Z = Et R = iPr R, = Cl R, = H R 3 = H R 4 = H R, = Cl χ = S Y = H Z = Et R = cPen R, = Cl R, = H R 3 = H R 4 = H R, = Cl X = S Y = H Z = Et R = cEs R, = Cl R, = H R 3 = H R 4 = H R, = Cl X = S Y = H Z = CH 3 R = iPr R, = F R, = H R 3 = H R 4 = H R< = F X = S Y = H Z = CH 3 R = (Bu R, = F R 2 = H R 3 = H R 4 = H R, = F X = S Y = H Z = CH 3 R = nBu R, = F R, = H R 3 = H R = H R, = F X = S Y = H Z = CH 3 R = sBu R, = F R, = H R 3 = H R 4 = H R, = F χ = S Y = H Z = CH 3 R = cPen R, = F R, = H R 3 = H R 4 = H R, = F X = S Y = H Z = CH 3 R = cEs R, = F R, = H R 3 = H R 4 = H R, = F X = S Y = H Z = Et R = /Pr R, = F R : = H R, = H R = H R, = F X = S Y = H Z = Et R = cPen R, = F R, = H R 3 = H R 4 = H R, = F X = S Y = H Z = Et R = cEs R, = F R, = H R 3 = H R = H R, = F X=S Y = H Z=CH, R= cEs -CH=CH-CH=CH R 3 =H R =H R,=H X = S Y = H Z = H R = sBu R, = Cl R, = H R 3 = H R 4 = H R, = H X = S Y = CH, Z = H R = sBu R, = F R, = H R, = H R = H R, = H X = S Y = CH 3 Z = H R = sBu R, = Cl R, = H R 3 = H R 4 = H R, = Cl X = S Y = CH 3 Z = H R = CH 3 R, = F R, = H R 3 = H R = H R 5 = F X = S Y = CH 3 Z = H R = iPr R, = F R, = H R 3 = H R 4 = H R, = F X = S Y = CH, Z = H R = nBu R, = F R, = H R 3 = H R 4 = H R, = F X = S Y = CH, Z = H R = iBu R, = F R, = H R 3 = H R = H R 5 = F X = S Y = CH 3 Z = H R = 5Bu R, = F R, = H R, = H R = H R, = F X = S Y = CH, Z = H R = cPen R, = F R, = H R, = H R 4 = H R, = F X = S Y = CH 3 Z = H R = cEs R, = F R, = H R 3 = H R 4 = H R, = F X = S Y = CH 3 Z = CH 3 R = CH 3 R, = F R, = H R 3 = H R 4 = H R, = F X = S Y = CH 3 Z = CH 3 R = sBu R, = F R, = H R 3 = H R 4 = H R, = F X = S Y = CH,Z = CH 3 R = cPe R, = F R, = H R 3 = H R 4 = H R, = F X = S Y = Et Z = H R = sBu R, = F R, = H R, = H R 4 = H R 5 = F X = S Y = JPr Z = H R = JPr R, = F R, = H R 3 = H R = H R, = F X = S Y = CH 3 Z = CH 3 R = iPr R, = F R, = H R, = H R 4 = H R, = F X = S Y = CH 3 Z = CH 3 R = «Bu R, = F R, = H R 3 = H R = H R, = F X = S Y = CH 3 Z = CH 3 R = Bu R, = F R, = H R, = H R 4 = H R 5 = F X = S Y = CH 3 Z = CH 3 R = cEs R, = F R, = H R, = H R 4 = H R, = F X = S Y = H Z = H R=MeSMe R, = F R, = H R 3 = H R 4 = H R 5 = F X = S Y = CH 3 Z = H R=MeSMe R, = F R, = H R 3 = H R 4 = H R, = F X = S Y = Et Z = H R=MeSMe R, = F R, = H R 3 = H R 4 = H R, = F X = S Y = iPr Z = H R=MeSMe R, = F R, = H R- = H R 4 = H R 5 = F. 4. A compound having formula A as claimed in claim 1 wherein X = NH Y = H Z = H R = Et R, = F R, = H R, = H R 4 = H R, = F X = NH Y = H Z = H R = «Pr R, = F R, = H R 3 = H R 4 = H R, = F X = NH Y = H Z = H R = zPr R, = F R, = H R 3 = H R 4 = H R, = F X = NH Y = H Z = H R = cPr R, = F R, = H R 3 = H R 4 = H R 5 = F X = NH Y = H Z = H R = nBu R, = F R, = H R 3 = H R 4 = H R 5 = F X = NH Y = H Z = H R = sBu R, = F R, = H R 3 = H R 4 = H Rs = F X = NH Y = H Z = H R=MeOEt R, = F R, = H R 3 = H R 4 = H R, = F X = NH Y = H Z = H R = cPe R, = F R 2 = H R 3 = H R 4 = H R 5 = F X = NH Y = H Z = H R = cEs R, = F R, = H R 3 = H R 4 = H R 5 = F X = NH Y = H Z = CH 3 R = cPe R, = F R, = H R 3 = H R 4 = H R 5 = F X = NH Y = CH, Z = H R = iPr R, = F R, = H R 3 = H R 4 = H R 5 = F X = NH Y = CH 3 Z = H R = sBu R, = F R, = H R 3 = H R 4 = H R 5 = F X = NH Y = CH 3 Z = H R = cPe R, = F R, = H R, = H R 4 = H R, = F X = NH Y = CH 3 Z = H R = benz R, = F R, = H R 3 = H R 4 = H R 5 = F X = NH Y = CH 3 Z = CH 3 R = cPe R, = F R, = H R 3 = H R 4 = H R < = F X = NH Y = H Z = H R = CH 3 R, = F R, = H R 3 = H R 4 = H R, = F X = NH Y = CH, Z = H R = CH 3 R, = F R, = H R, = H R = H R, = F X = NH Y = CH 3 Z = H R = nPr R, = F R, = H R 3 = H R 4 = H R < = F X = NH Y = CH, Z = H R = nBu R, = F R, = H R 3 = H R = H R < = F X = NH Y = H Z = CH 3 R = CH, R, = F R : = H R 3 = H R = H R < = F X = NH Y = H Z = CH 3 R = nPr R, = F R : = H R 3 = H R = H R < = F X = NH Y = H Z = CH 3 R = iPr R, = F R, = H R, = H R 4 = H R, = F X = NH Y = H Z = CH 3 R = «Bu R, = F R : = H R 3 = H R 4 = H R, = F X = NH Y = H Z = CH 3 R = sBu R, = F R 2 = H R 3 = H R 4 = H R, = F X = NH Y = H Z = CH, R = cEs R, = F R, = H R 3 = H R = H R, = F X = NH Y = CH, Z = CH 3 R = CH, R, = F R : = H R, = H R 4 = H R, = F X = NH Y = CH 3 Z = CH 3 R = ΛBU R, = F R, = H R 3 = H R = H R < = F X = NH Y = CH, Z = CH 3 R = cEs R, = F R, = H R 3 = H R = H R,- = F X = N Y = H Z = H R=(CH 3 ), R, = F R, = H R 3 = H R = H R, = F X = N Y = H Z = H R=Me-Pιp R, = F R, = H R 3 = H R = H R, = F X = N Y = H Z = H R= Moφh R, = F R, = H R 3 = H R = H R ; = F X = N Y = H Z = H R=S-morp R, = F R, = H R 3 = H R 4 = H R, = F X = N Y = H Z = H R= Piper R, = F R 2 = H R 3 = H R 4 = H R 5 = F X = N Y = H Z = H R=Pyrroh R, = F R, = H R 3 = H R 4 = H R < = F X = N Y = H Z = H R = Et, R, = F R- = H R 3 = H R 4 = H R« = F X = N Y = H Z = H R=(«Pr) : R, = F R, = H R 3 = H R 4 = H R, = F X = N Y = CH 3 Z = H R=(CH 3 ) 2 R, = F R , = H R 3 = H R 4 = H R, = F X = N Y = CH 3 Z = H R=Me-Pιp R, = F R, = H R 3 = H R 4 = H R,- = F X = N Y = CH, Z = H R= Morph R, = F R, = H R 3 = H R = H R, = F X = N Y = CH 3 Z = H R=S-moφ R, = F R, = H R 3 = H R 4 = H R, = F. 5. A pharmaceutically acceptable salt or soluble derivative of a compound of claim 1. 6. A process for the preparation of a compound having formula A as claimed in claim 1 wherein X = 0, wherein the proper methyl arylacetylalkylacetate is reacted with O- methylisourea in presence of calcium hydroxide; the so obtained 2-O-methyl(5-alkyl)-6- benzyl(substituted)uracils are reacted with the proper potassium alkoxide according to scheme A. 7. A process for the preparation of a compound having formula A as claimed in claim 1 wherein X = S, wherein the proper ethyl arylacetylalkylacetate is reacted with thiourea in presence of sodium methoxide; the so obtained 5-alkyl-6-benzyl(substituted)-2- thiouracils are reacted with methyl iodide or with an alkyl halide in a basic medium according to scheme B. 8. A process for the preparation of the compounds having formula A as claimed in claim 1 wherein X = NK (wherein K is -H, -C,. 4 alkyl. -C 3 . ή cycloalkyl), wherein the proper S- methyl(5-alkyl)-6-benzyl(substituted)-2-thiouracil is reacted with the proper amine according to scheme C. 9. A method of preventing infection of HIV, or of treating infection by HIV or of treating AIDS, comprising administering to a mammal an effective amount of a compound as claimed in claim 1 or a pharmaceutically acceptable salt or soluble derivative thereof. 10. A pharmaceutical composition useful for inhibiting HIV reverse transcriptase, comprising an effective amount of a compound claimed in claim 1 or a pharmaceutically acceptable salt or soluble derivative thereof, and a pharmaceutically acceptable carrier. 11. A pharmaceutical composition useful for preventing or treating infection of HIV or for treating AIDS, comprising an effective amount of a compound as claimed in claim 1 or a pharmaceutically acceptable salt or soluble derivative thereof, and a pharmaceutically acceptable carrier. 12. A method of preventing infection of HIV, or of treating infection by HIV or of treating AIDS, comprising administering to a mammal an effective amount of a compound as claimed in claim 1 or a pharmaceutically acceptable salt or soluble derivative thereof in combination with another anti-HIV agent selected from the group consisting of abacavir, zidovudine, BILA 1906, BILA 2185, BM+51.0836: triazoloisoindolinone derivative, BMS 186,318: aminodiol derivative HIV-1 protease inhibitor, d4API, stavudine, efavirenz, HBY097, HEPT, KNI-272, L-697,593, L-735,524, L-697,661, L-FDDC, L- FDOC, nevirapine, foscarnet, PMEA, PMPA, Ro 31-8959, RPI-3121, SC-52151, SC- 55389A, TIBO R82150, TIBO 82913, TSAO-m3T, U90152, UC: thiocarboxanilide derivatives, UC-781, UC-82, VB 11,328, amprenavir, XM 323, delaviridine, famciclovir, gancyclovir, penciclovir, indinavir, nelfinavir, ritonavir, saquinavir, DDI, DDC, Delaviridine, β-LddA, β-L-3'-azido-d5FC, carbovir, acyclovir, interferon, stavudine, (3'-azido-2',3'-dideoxy-5-methyl-cytidine), 3'-azido nucleosides, β-D-dioxolane nucleosides such as β-D-dioxolanylguanine (DXG), β-D-dioxolanyl-2,6-diaminopurine (DAPD), and β-D-dioxolanyl-6-chloropurine (ACP), D4T, FTC, 3TC, AZDU, and amprenavir.

Inventors: ARTICO MARINO, LA COLLA PAOLO, ARTICO, MARINO, LA COLLA, PAOLO
Applicants: ARTICO MARINO, COLLA PAOLO, NOVIRIO PHARMACEUTICALS LIMITE, ARTICO, MARINO, LA COLLA, PAOLO, NOVIRIO PHARMACEUTICALS LIMITED
Application year: 1999
Main classification: C07D239
IPC codes: C07D239